RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma
- PMID: 40883414
- DOI: 10.1038/s41388-025-03550-6
RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma
Abstract
Programmed death ligand 1 (PD-L1) is a protein expressed in hepatocellular carcinoma (HCC) that drives immune evasion by binding to programmed death receptor 1 (PD-1) on activated T cells. Understanding PD-L1 regulation is essential to understand the immunosuppressive microenvironment for antitumor immunity. We screened ribonucleic acid (RNA)-binding motif proteins (RBMs). RBM30 can enhance PD-L1 expression in HCC cells. In this study, we found that high RBM30 expression in tumor tissues can drive HCC tumor immune evasion and accelerate disease progression via increased PD-L1 transcription. We conducted multiple molecular and high-throughput assays to elucidate the intrinsic molecular mechanisms by which RBM30 upregulates PD-L1 expression in HCC. RBM30 binds to DNA near the transcriptional start site of STAT1 and recruits DOT1L to promote H3K79me3 enrichment, enhancing its accessibility to upregulate STAT1 transcription, consequently activating the PD-L1 transcription. This enhances PD-L1 expression to facilitate immune evasion. These findings reveal the vital role of RBM30 in HCC immune evasion.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The experimental protocol was approved by the Institutional Ethics Review Board of The Affiliated Taizhou People’s Hospital of Nanjing Medical University (2022-008-01). Animal ethical certificates were approved by the Experimental Center of Jiangsu Hanjiang Biotechnology Co., Ltd (HJSW-23050302), and the animals were raised according to animal welfare laws.
Similar articles
-
Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-L1.Int Immunopharmacol. 2025 Aug 28;161:115024. doi: 10.1016/j.intimp.2025.115024. Epub 2025 Jun 9. Int Immunopharmacol. 2025. PMID: 40494207
-
FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.Apoptosis. 2024 Oct;29(9-10):1529-1545. doi: 10.1007/s10495-024-01982-1. Epub 2024 Jun 2. Apoptosis. 2024. PMID: 38824477
-
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12. Immunotherapy. 2025. PMID: 40353308
-
The role of E3 ligases and deubiquitinases in PD-L1 regulation and the tumor microenvironment in renal cell carcinoma.Med Oncol. 2025 Jul 29;42(9):389. doi: 10.1007/s12032-025-02878-z. Med Oncol. 2025. PMID: 40728589 Review.
-
Cancer cell-derived extracellular vesicles: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies.Front Immunol. 2025 Jun 12;16:1601266. doi: 10.3389/fimmu.2025.1601266. eCollection 2025. Front Immunol. 2025. PMID: 40574844 Free PMC article. Review.
References
-
- Endo Y, Sasaki K, Moazzam Z, Woldesenbet S, Yang J, Araujo Lima H, et al. The impact of a liver transplant program on the outcomes of hepatocellular carcinoma. Ann Surg. 2023;278:230–8. - PubMed
-
- Brown Z, Tsilimigras D, Ruff S, Mohseni A, Kamel I, Cloyd J, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–20. - PubMed
-
- He M, Huang Y, Du Z, Lai Z, Ouyang H, Shen J. et al. Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clin Cancer Res. 2023;29:5104–5115. https://doi.org/10.1158/1078-0432.CCR-23-0060 . - PubMed
-
- Zanuso V, Rimassa L, Braconi C. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology. 2025;81:1365–1386. https://doi.org/10.1097/HEP.0000000000000572 . - PubMed
-
- Yu S. Immunotherapy for hepatocellular carcinoma: recent advances and future targets. Pharmacol Ther. 2023;244:108387. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous